Anticancer agent 300
Anticancer agent 300 (compound P14) is a CCND1, CDK4, CDK6, and CCNE1 modulator, with anti-proliferative, cell-cycle modulatory, senescence-inducing, and apoptosis-inducing activity. Anticancer agent 300 can be used for the research of ER+/HER2− breast cancer and BRAF-mutant melanoma.
For research use only. We do not sell to patients.
- CAS No.: 1310059-06-3
- Formula: C24H19N3OS2
- Molecular Weight:429.56
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Anticancer agent 300 (P14) (5-50 μM; 7 days) significantly reduces colony-forming capacity in MCF7 and A375 cells and induces cytotoxicity in non-tumoral TC28a2 cells at high concentrations[1].
Anticancer agent 300 (P14) (5-50 μM; 7 days) has an IC50 of 2.018 μM in MCF7 cells and 1.887 μM in A375 cells[1].
Anticancer agent 300 (P14) (5 μM; 12 days) significantly reduces spheroid area in MCF7 and A375 3D cultures[1].
Anticancer agent 300 (P14) (5 μM; 7 days) reduces the proportion of G2/M phase cells in MCF7 and A375 cells[1].
Anticancer agent 300 (P14) (5 μM; 7 days) modulates the expression of cell-cycle-related genes in a cell-type-specific manner, upregulating G1/S transition genes in MCF7 cells and downregulating them in A375 cells[1].
Anticancer agent 300 (P14) (5 μM; 7 days) increases the expression of senescence-associated genes in MCF7 and A375 cells[1].
Anticancer agent 300 (P14) (5 μM; 7 days) upregulates SASP factors in MCF7 cells and reduces their synthesis in A375 cells[1].
Anticancer agent 300 (P14) (5 μM; 7 days) increases cell death and early apoptosis in MCF7 and A375 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MCF7, A375, TC28a2
-
Concentration:5, 20, 35, 50 μM
-
Incubation Time:7 days
-
Result:Significantly reduced the colony-forming capacity of MCF7 and A375 cells in a dose-dependent manner. Demonstrated potent anti-proliferative effects even at 5 μM in both cell lines.
Induced cytotoxicity in non-tumoral TC28a2 cells at high concentrations (up to 20 μM).
-
Cell Line:MCF7, A375
-
Concentration:5, 20, 35, 50 μM
-
Incubation Time:7 days
-
Result:Achieved an IC50 of 2.018 μM in MCF7 cells and 1.887 μM in A375 cells.
-
Cell Line:MCF7, A375
-
Concentration:5 μM
-
Incubation Time:12 days
-
Result:Significantly reduced spheroid area in MCF7 cells after 8 and 12 days of treatment, and in A375 cells with a less marked but still statistically significant reduction.
-
Cell Line:MCF7, A375
-
Concentration:5 μM
-
Incubation Time:7 days
-
Result:Reduced the proportion of cells in the G2 phase in both cell lines: decreased MCF7 cells' G2/M phase proportion from 26.25% (control) to 13.10%, and A375 cells' G2/M phase proportion from 5.44% (control) to 0.52%.
-
Cell Line:MCF7, A375
-
Concentration:5 μM
-
Incubation Time:7 days
-
Result:Significantly upregulated genes associated with G1/S transition and S-phase entry in MCF7 cells.
Significantly downregulated key regulators of the G1/S transition and S-phase entry, including CCND1, CDK4, CDK6, and CCNE1, in A375 cells.
Notably increased the expression of senescence-associated factors, including p21, p53, and p53-responsive genes (IGFBP3 and GDF15), in both cell lines.
Significantly upregulated classical SASP components, including IL-6 and IL-8, in MCF7 cells.
Showed a trend toward reduced synthesis of SASP factors in A375 cells.
-
Cell Line:MCF7, A375
-
Concentration:5 μM
-
Incubation Time:7 days
-
Result:Showed a tendency to increase cell death and the proportion of cells undergoing early apoptosis in both cell lines.
Chemical Information
-
CAS No. 1310059-06-3
-
Molecular Weight 429.56
-
Formula C24H19N3OS2
-
SMILES
C12=C(SC(C3=CC(C4=CC5=C(S4)C=CC=C5)=NC(N6CCOCC6)=N3)=C2)C=CC=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anticancer agent 300 Related Classifications
HY-181131 Related Classifications
Powered by Bioz